Brand names: Visipaque
Radiographic Contrast Agent · X-Ray Contrast Activity
Route: Intravascular
FDA Black Box Warning
WARNING: NOT FOR INTRATHECAL USE Inadvertent intrathecal administration may cause death, convulsions/seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema [see Contraindications (4) and Warnings and Precautions (5.1) ] . WARNING: NOT FOR INTRATHECAL USE See full prescribing information for complete boxed warning Inadvertent intrathecal administration may cause death, convulsions/seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema. ( 4 , 5.1 )
Contraindications
4 CONTRAINDICATIONS VISIPAQUE is contraindicated for Intrathecal use [see Warnings and Precautions (5.1) ] . Not indicated for intrathecal use. ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary There are no data with iodixanol use in pregnant women to inform any drug-associated risks. In animal reproduction studies, no developmental toxicity occurred with intravenous iodixanol administration to rats and rabbits at doses up to 0.24 (rat) or 0.48 (rabbit) times the maximum recommended human intravenous dose ( see Data ). All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data Reproduction studies were performed in rats and rabbits with intravenous administration of iodixanol at doses up to 2 g Iodine/kg, daily, from implantation of the embryo (gestation day 7 in rat; 6 in rabbit) through closure of the hard palate (gestation day 17 in rats; 18 in rabbits). No maternal toxicity occurred, and no adverse effects occurred on fetal survival, embryo-fetal development, or the ability of dams to rear a litter.
4 interactions on record
Iodixanol may increase risk of metformin-induced lactic acidosis, possibly by worsening renal function. Stop metformin prior to iodixanol administration in patients with eGFR 30-60 mL/min/1.73 m² or hepatic impairment, alcoholism, or heart failure.
Source: NLP:iodixanol
Beta-blockers lower the threshold for contrast reactions, increase severity of reactions, and reduce responsiveness to epinephrine treatment. Use caution when administering iodixanol to patients taking beta-blockers.
Source: NLP:iodixanol
Renal toxicity reported in patients with liver dysfunction receiving oral cholecystographic agent followed by iodixanol. Postpone iodixanol administration in patients who recently received oral cholecystographic contrast.
Source: NLP:iodixanol
Iodixanol may interfere with thyroid uptake of radioactive iodine (I-131 and I-123), decreasing therapeutic and diagnostic efficacy in thyroid carcinoma patients for 6 to 8 weeks.
Source: NLP:iodixanol